Figure 4
From: Immunomodulatory role of Parkinson’s disease 7 in inflammatory bowel disease
Effect of PARK7 silencing on TNFA, IL1B, IL6, IL10 and TGFB1 expression of HT-29 cells. Cells were transfected either with scRNA or PARK7 specific siRNA (a–g) and a group of transfected cells was also treated with IL-17 (c–e, g). The mRNA expression of PARK7, TNFΑ, IL1Β, IL6, IL10 and TGFB1 was determined by real-time PCR (a–d), and the protein level of PARK7 (a, c, f, g) and TNF-α (e) by Western blot (a, c, f, g) or ELISA (e), respectively (n = 4–6). Relative expression levels are presented in comparison with Gapdh mRNA (a–d), GAPDH (a, f) or ß-actin protein (c, g) as internal control and normalized to vehicle treated group. Results are illustrated as mean + SEM, dots represent individual values. Analysis of significance was performed by Mann–Whitney or Kruskal–Wallis test. #p < 0.05 comparing the connected groups. Full-length blots are included in “Supplementary Informations”.
